This information is for educational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional.
LONSURF 15 MG/6,14 MG COMPRIMIDOS RECUBIERTOS CON PELICULA — Description, Dosage, Side Effects | PillsCard
OTC
LONSURF 15 MG/6,14 MG COMPRIMIDOS RECUBIERTOS CON PELICULA
15 mg / 6.14 mg, COMPRIMIDO RECUBIERTO CON PELÍCULA
INN: TRIFLURIDINA, TIPIRACILO
Data updated: 2026-04-11
Available in:
🇨🇿🇩🇪🇬🇧🇪🇸🇵🇹🇸🇰
Form
COMPRIMIDO RECUBIERTO CON PELÍCULA
Dosage
15 mg / 6.14 mg
Route
VÍA ORAL
Storage
—
User Reviews
Reviews reflect personal experiences and are not medical advice. Always consult your doctor.
About This Product
Manufacturer
Les Laboratoires Servier (ES)
ATC Code
L01B
Source
CIMA
(
ARTG
)
Colorectal cancer
LONSURF is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with, or are not considered candidates for fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents.,Gastric cancer
LONSURF is indicated for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy.